Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase III, Randomised, Double-blind, Two-arm Study to Investigate the Efficacy and Safety of Treatment With CHF10196 Tablets (Florensocatib) Compared With Placebo for up to 78 Weeks, Followed by an Open-label Extension, in Male and Female Participants 12 to 85 Years of Age With Bronchiectasis

NCT07577804 is registered in ClinicalTrials.gov with Chiesi Farmaceutici S.p.A. as lead sponsor.

NCT NCT07577804
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07577804 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase III, Randomised, Double-blind, Two-arm Study to Investigate the Efficacy and Safety of Treatment With CHF10196 Tablets (Florensocatib) Compared With Placebo for up to 78 Weeks, Followed by an Open-label Extension, in Male and Female Participants 12 to 85 Years of Age With Bronchiectasis
Lead sponsor
Chiesi Farmaceutici S.p.A.
Phase
Phase 3
Overall status
Not yet recruiting
Start date
November 30, 2026
Completion date
April 30, 2030
Enrollment
904 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

bronchiectasis